Klotho Neurosciences (KLTO)announced that the FDA has granted Orphan Drug Designation to the company’s novel secreted-Klotho promoter, gene and delivery system for the treatment of ALS.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLTO:
- Klotho Neurosciences amyotrophic lateral sclerosis treatment gets orphan status
- 3 Penny Stocks to Watch Now, 7/1/25
- Klotho Neurosciences Begins Manufacturing Gene Therapy for ALS
- Klotho Neurosciences moves forward with KLTO-202 manufacturing and development
- Klotho Neurosciences, ORCLS announce plan to study Blue Zone